Category Archives: Population(s)

Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis

2024

INTRODUCTION: Among many antiretroviral drugs, tenofovir alafenamide is used extensively in combination regimens of tenofovir/emtricitabine or tenofovir/emtricitabine/bictegravir. However, concerns have arisen about the potential of tenofovir alafenamide to exacerbate hyperlipidaemia....

A scoping review of interventions targeting HIV stigma in women living with HIV

2024

Since its initial detection in the 1980s, AIDS has become a significant global health threat, disproportionately affecting women. Stigma constitutes the substantial barrier to accessing healthcare for women living with...

A systematic review and meta-analysis evaluating the effectiveness of minimally supervised home and community exercise interventions in improving physical activity, body adiposity and quality of life in adults living with HIV

2024

People living with HIV (PLWH) are physically inactive and risk cardiometabolic dysfunction. Home and community exercise (HCE) is pragmatic, cost-effective and improves health in varied chronic conditions. This review aimed...

HIV prevention product acceptability and preference among women in Sub-Saharan Africa to inform novel biomedical options in development: A systematic review

2024

The availability of several HIV prevention options may allow women to choose a product that suits their lifestyle and preferences. Product attributes and contextual factors influence product acceptability, which affects...

Population pharmacokinetic simulations for dose optimization of tenofovir disoproxil fumarate in HIV-infected patients with moderate-to-severe renal impairment

2024

Tenofovir disoproxil fumarate (TDF) requires dosage adjustments from the standard 300 mg once daily to every 48–96 h for moderate-to-severe renal impairment to avoid excessive exposure. However, this extended interval...

Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir

2024

INTRODUCTION: Lenacapavir is the first HIV-1 capsid inhibitor administered subcutaneously twice yearly. While lenacapavir is currently only indicated as salvage therapy, it has the potential to become a foundation of...

Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women living with HIV: A systematic review and meta-analysis

2024

OBJECTIVE: Women living with HIV (WLHIV) are at increased risk of adverse perinatal outcomes compared to HIV-negative women, despite antiretroviral therapy (ART). There is evidence that the risk of adverse...

Influence factors associated with fertility intention among people living with HIV in China and other regions: A systematic review and meta-analysis

2024

Background Advances in medical care and improved quality of life have fostered a growing desire for parenthood among people living with HIV (PLHIV). However, this desire remains inadequately addressed in...

Acceptability and use of HIV self-testing among young people in sub-Saharan Africa: A mixed methods systematic review

2024

Background Young people (YP) are disproportionately affected by the HIV pandemic in sub-Saharan Africa (SSA), but testing rates remain low despite global targets of testing 95% of people with HIV...

Vaginal microbiome and the risk of preterm birth in women living with HIV: A scoping review

2024

There are sparse data on the role of theAÿvaginal microbiome (VMB) in pregnancy among pregnant women living with HIV (PWLWH) and its association with spontaneous preterm birth (sPTB). We conducted...

Neuropsychiatric adverse events in tenofovir disoproxil fumarate- and tenofovir alafenamide-based HIV therapy and prophylaxis: A systematic review and meta-analysis

2024

INTRODUCTION: Tenofovir is integral to antiretroviral therapy (ART) and preexposure prophylaxis (PrEP) for HIV, but its neuropsychiatric adverse events (NPAEs) have not been systematically investigated. OBJECTIVES: This systematic review aims...

Doxycycline post-exposure prophylaxis for bacterial sexually transmitted infections: The current landscape and future directions

2024

PURPOSE OF REVIEW: The incidence of bacterial sexually transmitted infections (STI) continues to rise particularly among men who have sex with men (MSM). Doxycycline post-exposure prophylaxis (doxy-PEP) has emerged as...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!